Sameer Sharma
Vice President & Head, Translational Drug Discovery @Alphameld Corporation
Signup · Get unlimited contacts
WORK HISTORY
Vice President & Head, Translational Drug Discovery @Alphameld Corporation
Driving the mission to transform the drug discovery and development process with AI-powered technology to enhance human health and quality of life. Utilizing artificial intelligence to augment data analysis, identifying novel targets across major therapeutic areas, and investigating disease-drug combinations for rare and common diseases.
EDUCATION
Jamia Hamdard
Bachelor of Pharmacy, Pharmaceutical Sciences
Panjab University, Chandigarh
Ph.D. (Institute of Microbial Technology-Panjab University (UIPS) Partnership; SRF-DRDO Funded), Pharmacology
Panjab University, Chandigarh
Masters of Pharmacy, Pharmacology
SKILLS
ABOUT SAMEER SHARMA
Strategic Drug Discovery & Development Expert with 20+ years of experience leveraging AI/ML to accelerate the pipeline from target identification to clinical candidate. Proven leader in identifying novel disease-drug combinations for rare and common disorders, with deep expertise in due diligence for in-licensing late-stage assets.Key ExpertiseAI-Driven Discovery: Leveraged big data analytics and AI to identify novel targets across major therapeutic areas, including inflammatory (skin, gut, liver), CNS, and hematology disorders. Translational Leadership: Directing R&D strategies, overseeing Animal Proof of Concept (POC), and managing regulatory studies to bridge the gap between discovery and the clinic. Regulatory Milestones: Proven track record in filing Investigational New Drug (IND) applications and delivering clinical-ready pipelines.Major Achievements BioXcel Therapeutics: Served as Lead Researcher for the discovery of BXCL501 (IGALMI™), a sublingual film for neuropsychiatric agitation that was successfully launched in the US in 2022 (NASDAQ:BTAI). Invea Therapeutics: Orchestrated translational R&D strategies to generate AI enabled-clinical ready candidates and securing regulatory path. Developed two discovery programs for Invea within 3 years; one is ready to enter Clinical Phase 2A, while the second is a novel oral small molecule in the preclinical phase.Centrexion: Provided high-level strategic insights to align disease indications for assets currently in Phase 2 clinical trials. Program Leadership: Led multiple projects and collaborations at Daiichi Sankyo and Ranbaxy Research Laboratories across autoimmune, respiratory, and metabolic research. Thought Leadership: Authored 2 book chapters and 20 peer-reviewed publications with over 2,400 citations.Intellectual Property Portfolio: Named inventor on 16 patent families (4 issued U.S. patents and 12 published U.S. patent applications. Extensive international filings/foreign counterparts. Among the inventions claimed are AI-driven discovery methodologies and innovative therapeutic approaches for disease states.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.